Wells Fargo raised the firm’s price target on Annexon (ANNX) to $27 from $14 and keeps an Overweight rating on the shares. The firm is raising its probability of success to 55% from 10% that vonaprument’s Phase 3 trial in GA will be positive in the second half of 2026. Wells believes the setup offers a significant, asymmetric risk/reward skew with the potential for VC-like upside in the next 12 months.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon price target lowered to $8 from $9 at BofA
- Annexon Biosciences Completes Successful Public Offering
- Annexon 25.1M share Spot Secondary priced at $2.60
- Annexon announces $75M common stock, warrants offering
- Annexon Biosciences: Promising Advancements in Late-Stage Complement Inhibitors Drive Buy Rating